Xalud: Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain

NEW YORK--(BUSINESS WIRE)-- Xalud Therapeutics, a clinical-stage biotechnology company developing DNA-delivered therapeutics, today announced the first patient dosed in a Phase 2a clinical trial of it...